Overview

Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
Phase:
Phase 3
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Collaborator:
Eli Lilly and Company
Treatments:
Fluoxetine